You are on Trendlyne United States. Click here to go to India website or make United States as your default
  1. MARKETS
  2. SECTOR : PHARMACEUTICALS & BIOTECHNOLOGY
  3. INDUSTRY : MAJOR PHARMACEUTICALS
  4. REDHILL BIOPHARMA - ADR

Redhill Biopharma - ADR XNAS: RDHL

Redhill Biopharma - ADR Live Share Price Today, Share Analysis and Chart

Download real time

2.99 0.19 (6.79%)

85.26% Fall from 52W High

108.6K XNAS Volume

XNAS 21 Mar, 2025 5:30 PM (EDT)

Watchlist

Portfolio

Share
Durability score
Not Eligible
-
Valuation Score
Expensive Valuation
0.3 / 100
Momentum Score
Technically Bearish
26.0 / 100
Analyst Price Target
No estimates available

9

S

11

W

1

O

1

T

SWOT Analysis

Check P/E Buy Sell Zone

Not enough data available


Redhill Biopharma - ADR Live Price Chart

Switch to TradingView
Fetching data ...

Redhill Biopharma - ADR Stock Analysis

Redhill Biopharma - ADR stock analysis with key metrics, changes, and trends.

Redhill Biopharma - ADR MetricVALUECHANGE %TRENDANALYSIS
Annual Revenue$6.53 M81.73%negative

Annual Revenue fell 81.73%, in the last year to $6.53 M. Its sector's average revenue growth for the last fiscal year was 7.46%.

Annual Net Profit$23.92 M106.67%positive

Annual Net Profit rose 106.67% in the last year to $23.92 M. Its sector's average net profit growth for the last fiscal year was -32.43%.

Stock Price$2.99-76.46%negative

Stock Price fell 76.46% and underperformed its sector by 85.53% in the past year.

Debt to Equity Ratio0.57-positive

Debt to Equity Ratio of 0.57 is less than 1 and healthy. This implies that its assets are financed mainly through equity.

Interest Coverage Ratio66.26-positive

Interest Coverage Ratio is 66.26, higher than 1.5. This means that it is able to meet its interest payments comfortably with its earnings (EBIT).

Institutional Holding1.28 %0.85%positive

Institutional Holding increased by 0.85% in the last quarter to 1.28.

VIEW LESS


Loading data..

Redhill Biopharma - ADR - Company Profile

What does Redhill Biopharma - ADR do?

Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company is focused primarily on the advancement of its development pipeline of clinical-stage therapeutic candidates. The company also commercializes in the U.S. GI-related products, Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin). The company's current pipeline consists of five therapeutic candidates, which are Opaganib, RHB-107, RHB-102, RHB-204, and RHB-104, most of which are in clinical development.

Redhill Biopharma - ADR Management structure

All Gross Remunerations are in USD
Mr. Dror Ben-Asher
Chairman of the Board and Chief Executive Officer
594.61 K
2023
Gross Remuneration
Year
Mr. Rick D. Scruggs
Director and Chief Commercial Officer
469.8 K
2023
Gross Remuneration
Year
Mr. Gilead Raday
Chief Operating Officer
379.96 K
2023
Gross Remuneration
Year
Mr. Razi Ingber
Chief Financial Officer
354.22 K
2023
Gross Remuneration
Year
Mr. Adi Frish
Chief Corporate and Business Development Officer
353.7 K
2023
Gross Remuneration
Year

Redhill Biopharma - ADR Board of directors

All Gross Remunerations are in USD
Mr. Rick D. Scruggs
Director and Chief Commercial Officer
-
2022
Gross Remuneration
Year
Mr. Eric Swenden
Independent Director
-
2022
Gross Remuneration
Year
Dr. Shmuel Cabilly
Independent Director
-
2022
Gross Remuneration
Year
Dr. Kenneth Reed
Independent Director
-
2022
Gross Remuneration
Year
Mr. Dror Ben-Asher
Chairman of the Board and Chief Executive Officer
-
2022
Gross Remuneration
Year
Mr. Ofer Tsimchi
Independent Director
-
2022
Gross Remuneration
Year

Redhill Biopharma - ADR FAQ

How is Redhill Biopharma - ADR today?
Redhill Biopharma - ADR today is trading in the green, and is up by 6.79% at 2.99.
Redhill Biopharma - ADR is currently trading up 6.79% on an intraday basis. In the past week the stock rose 16.80%. stock has been down -54.00% in the past quarter and fell -76.46% in the past year. You can view this in the overview section.